However, Chitnis et al., in their over 10-year long observation of patients enrolled within 5 years of disease onset in the Comprehensive Longitudinal Investigation of MS at the Brigham and Women’s Hospital (CLIMB) study, could not confirm a predictive value of serum NfL for EDSS worsening [59]. The gene discussed is NEFL; the disease is myeloid sarcoma.